Navigation Links
MiMedx Announces 2012 Results
Date:3/7/2013

Biologics acquisition earn out due to higher than expected tissue revenue. The Net Loss also includes approximately $1.6 million in non-cash related expenses including $780,000 in share-based compensation expense, $492,000 in non-cash refinancing expense tied to debt discounts, $263,000 in amortization of intangibles, and $111,000 in depreciation expense.

Use of non-GAAP financial measuresManagement has disclosed adjusted financial measurements in this press announcement that present financial information that is not in accordance with generally accepted accounting principles (GAAP). These measurements are not a substitute for GAAP measurements, although Company management uses these measurements as aids in monitoring the Company's on-going financial performance from quarter-to-quarter and year-to-year on a regular basis, and for benchmarking against other medical technology companies. Adjusted EBITDA* is earnings before interest, taxes, depreciation, amortization, share-based compensation, non-cash impairment and earn out liability charges. For a reconciliation of this non-GAAP financial measure to the most directly comparable financial measure, see accompanying table to this release. Adjusted financial measures used by the Company may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies. Investors should consider adjusted measures in addition to, and not as a substitute for, or superior to, financial performance measures prepared in accordance with GAAP. Revenue Breakdown The Company breaks down its revenues between three primary regenerative medicine specialties, "Wound Care," "Surgical & Sports Medicine," and "Other," and reports its revenue in these categories.  Revenue for the Company's EpiFix® grafts comprises the Wound Care category. Its Surgical & Sports Medicine specialty is comprised of the AmnioFix® product line which includes both membrane and injectable
'/>"/>

SOURCE MiMedx Group, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. MiMedx Group to Present at the 6th Annual OneMedForum
2. MiMedx Group to Present at the Stifel Nicolaus 2012 Healthcare Conference
3. CCS Medical Announces Agreement with LifeScan
4. HUYA Bioscience Announces Partnership With Shanghai Zhangjiang Biotech Pharmaceutical Base
5. AVANIR PHARMACEUTICALS ANNOUNCES RESEARCH COLLABORATION WITH DEPARTMENT OF VETERANS AFFAIRS FOR SCREENING PSEUDOBULBAR AFFECT (PBA) SYMPTOMS IN VETERANS WITH TRAUMATIC BRAIN INJURY
6. Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Impax Laboratories Inc.
7. Sangamo BioSciences Announces Presentation At The Barclays Global Healthcare Conference
8. DMH International Announces The Launch of TouchPACS
9. Psyche Systems Announces Availability of Toxicology LIS
10. Jazz Pharmaceuticals Announces Pricing Of Public Offering Of Ordinary Shares By Selling Shareholders
11. DDS Lab Announces Strategic Alliance with United Concordia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... , Aug. 3, 2015 Biosensors ... BIG SP; Reuters: BIOS.SI; SGX: B20), a developer, ... announced financial results for its first fiscal quarter ... Quarter Highlights and Recent Developments: ... in improving its cost structure, driven by lower ...
(Date:8/3/2015)... BOULDER, Colo., Aug. 3, 2015  Array BioPharma ... for the fourth quarter and full year of ... Ron Squarer, Chief Executive Officer of Array, noted, ... Phase 3, are on track for regulatory submissions ... in BRAF-mutant melanoma and BRAF-mutant colorectal cancer further ...
(Date:8/3/2015)... FLORHAM PARK, N.J. , Aug. 3, 2015 ... its primary and secondary endpoints in a phase III ... (OIC) in adult patients with chronic non-cancer pain. Naldemedine ... (PAMORA). This is the third Phase III trial in ... Study results showed that a 0.2 mg ...
Breaking Medicine Technology:Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 2Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 3Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 4Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 5Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 6Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 2Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 3Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 4Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 5Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 6Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 7Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 8Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 9Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 10Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 11Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 12Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 4
... 04, 2007 /PRNewswire/ -- Novagali Pharma, an,emerging ... positive results from the Phase III,clinical study ... (VKC). In this orphan disease, it was ... improved in patients,receiving Vekacia(R). Furthermore, the tolerability ...
... Phase III study of ERBITUX with,chemotherapy in ... primary endpoint of improving overall survival --, ... ImClone,Systems Incorporated and Bristol-Myers Squibb Company announced,today ... of ERBITUX(R) (Cetuximab),combined with platinum-based chemotherapy met ...
Cached Medicine Technology:Novagali Pharma Announces Positive Vekacia Clinical Results From,Pivotal Phase III Trial in Vernal Keratoconjunctivitis 2Survival Data Available From Erbitux Study in First-Line Treatment,of Advanced Head and Neck Cancer 2Survival Data Available From Erbitux Study in First-Line Treatment,of Advanced Head and Neck Cancer 3Survival Data Available From Erbitux Study in First-Line Treatment,of Advanced Head and Neck Cancer 4Survival Data Available From Erbitux Study in First-Line Treatment,of Advanced Head and Neck Cancer 5Survival Data Available From Erbitux Study in First-Line Treatment,of Advanced Head and Neck Cancer 6Survival Data Available From Erbitux Study in First-Line Treatment,of Advanced Head and Neck Cancer 7Survival Data Available From Erbitux Study in First-Line Treatment,of Advanced Head and Neck Cancer 8Survival Data Available From Erbitux Study in First-Line Treatment,of Advanced Head and Neck Cancer 9
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... ... as one of 20 finalists for America’s Favorite Veterinarian. The contest is put ... by a judging committee from 500 nominees. Nominees were evaluated on community involvement, ...
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... ... of higher learning, announced today that its RN to BSN and Master ... been awarded full accreditation through June 2020 from the Commission on Collegiate ...
(Date:8/4/2015)... ... 04, 2015 , ... Continuing Education Company (CEC) ... interaction simulation session entitled "NOACS: What the Evidence Shows in Managing AFib, ... Inc. and EDUmotion US LLC. , This special activity was recently presented during ...
(Date:8/4/2015)... ... 2015 , ... IN AMERICA and the program's host, James ... affects millions of Americans every single year. To help people obtain a better ... the latest segment produced with the assistance of several top medical professionals. ...
(Date:8/4/2015)... ... 04, 2015 , ... Healthcare IT News (HITN), ... in healthcare and technology markets, today announced significant spikes in website traffic and ... Health Record (EHR) decision. The DOD related numbers solidify HITN’s status as the ...
Breaking Medicine News(10 mins):Health News:Dr. Gary Richter, Oakland Holistic Veterinarian, Among 20 Finalists for America’s Favorite Veterinarian 2Health News:Dr. Gary Richter, Oakland Holistic Veterinarian, Among 20 Finalists for America’s Favorite Veterinarian 3Health News:Loyola University New Orleans Awarded Accreditation for its Online RN to BSN and MSN Programs 2Health News:Loyola University New Orleans Awarded Accreditation for its Online RN to BSN and MSN Programs 3Health News:Loyola University New Orleans Awarded Accreditation for its Online RN to BSN and MSN Programs 4Health News:Innovative Medical Interactive Simulation Session to be presented at upcoming Continuing Education Company Education (CME) Conferences. 2Health News:Innovative Medical Interactive Simulation Session to be presented at upcoming Continuing Education Company Education (CME) Conferences. 3Health News:Coverage of DOD’s EHR Decision Reinforces Healthcare IT News’ Leadership 2
... men treated with a combination of radiation seed implants ... cured of their disease 15 years// following their treatment, ... Journal of Radiation Oncology*Biology*Physics, the official journal of ASTRO. ... at the Seattle Prostate Institute. Doctors wanted to look ...
... circumcision procedure could reduce 50% of the HIV infection rate ... number of Ugandan men seeking it.// , ... reports, out of which nearly half were adults. Less than ... Institutes of Health found that new HIV infections among circumcised ...
... alleviate symptoms of early-stage Parkinson's disease, and may be ... the brain disorder,// researchers said., ,A neupro patch ... to study its effects on 277 people in Canada ... is designed to convey a drug called rotigotine ...
... Parkinson's appear to increase the risk of heart valve disease, ... disorder of the central nervous system that often impairs motor ... that keep blood flowing in the right direction through the ... blood may not move the way it should., ,The ...
... is the final awakening' - Walter Scott// ... the former president of Iraq, Saddam Hussein, was sent to the ... the fact that he slaughtered 148 fellow countrymen, who were Shias, ... put to use in all societies to wipe out political dissent. ...
... Inner city dwellings were thought to be far cleaner and ... say this is not true- inner cities are a haven// ... and TNS analyzed smoking and disease rates and dietary habits ... The analysis revealed that towns such as Merthyr Tydfil in ...
Cached Medicine News:Health News:'Hooded Horror': Death by Hanging 2Health News:'Hooded Horror': Death by Hanging 3
The CA method used on the Dade Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of calcium in serum....
For the quantitative in vitro determination of Total Protein in serum and plasma...
The LDH method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of lactate dehydrogenase activity in serum or plasma...
For the quantitative in vitro determination of Anti-Streptolysin-O (ASO) in serum....
Medicine Products: